Testing a new oral medication for moderate to severe rheumatoid arthritis

Plain-English translation of NCT07408024 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a new oral medication called TollB-001 to see if it can help people with moderate to severe rheumatoid arthritis (RA) whose disease has not improved enough with standard RA drugs. Researchers want to understand how safe the medication is, how your body processes it, and whether it reduces joint pain, swelling, and inflammation. About 24 people will participate in this early-stage trial.

People with rheumatoid arthritis often find that standard medications don't work well enough or cause side effects they can't tolerate. This trial exists to explore whether this new treatment could offer another option for patients who need better disease control.

Do you qualify?

You likely qualify if…

you are between 18 and 70 years old
you have been diagnosed with rheumatoid arthritis using standard diagnostic criteria
your rheumatoid arthritis is moderate to severe and currently active (shown by blood tests and joint symptoms)
you have tried at least one conventional RA medication and either it did not work well enough or you could not tolerate it
you are willing to stop your current RA medications during the study and use effective birth control if you are of childbearing age
you are able to visit the clinic for check-ups and take study medication as instructed

You likely don't qualify if…

you are allergic to TollB-001 or any of its ingredients
your rheumatoid arthritis is very severe and has left you wheelchair-bound or bedridden long-term
you have recently taken JAK inhibitors, biologic RA drugs, or other strong immune-suppressing medications
you have received steroid injections into your joints or blood within the past 4 weeks
you are pregnant, planning to become pregnant, or not willing to use reliable birth control during and for 3 months after the study

What participation looks like

You will take either the new medication or a placebo (a pill with no active ingredient) by mouth once a day for 4 weeks, then return for a follow-up visit one week after finishing. During the study, you will have blood tests and physical exams to check how well the medication is working and whether you are having any side effects. You will need to discontinue your current RA medications before starting the study drug.

AI-generated summary from trial data · Jun 11, 2026 · Not medical advice

Trial locations(6 sites)

China

The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality

Puyang Oilfield General Hospital, Puyang, Henan

Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia

Pingxiang People's Hospital, Pingxiang, Jiangxi